Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$62.1M+24.5%
CG Oncology logo
CG OncologyCGON
$33.7M-18.7%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$52.55M+3.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$161.66M-25.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s cash & equivalents?
Oric Pharmaceuticals, Inc. (ORIC) reported cash & equivalents of $56.4M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
Oric Pharmaceuticals, Inc.'s cash & equivalents increased by 14.3% year-over-year, from $49.33M to $56.4M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s cash & equivalents has grown at a -10.3% compound annual growth rate (CAGR), from $78.45M to $45.67M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.